Efficacy and Safety of Evinacumab for the Treatment of Hypercholesterolemia: A Meta-Analysis

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

(2020) Jan Borén et al.   EUROPEAN HEART JOURNAL

A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects

(2020) Mariko Harada-Shiba et al.   ATHEROSCLEROSIS

LDL-Cholesterol Reduction by ANGPTL3 Inhibition in Mice Is Dependent on Endothelial Lipase

(2020) Liya Wu et al.   CIRCULATION RESEARCH

Evinacumab for Homozygous Familial Hypercholesterolemia

(2020) Frederick J. Raal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evinacumab in Patients with Refractory Hypercholesterolemia

(2020) Robert S. Rosenson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia

(2019) Zahid Ahmad et al.   CIRCULATION

High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real‐World Administrative Claims Analysis of Statin‐Treated Patients With High Residual Cardiovascular Risk

(2018) Peter P. Toth et al.   Journal of the American Heart Association

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

(2018) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of Evinacumab, A Monoclonal Antibody to ANGPTL3, In Homozygous Familial Hypercholesterolemia

(2017) Daniel Gaudet et al.   Journal of Clinical Lipidology

Angiopoietin-like 3 in lipoprotein metabolism

(2017) Sander Kersten   Nature Reviews Endocrinology

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides

(2017) Mark J. Graham et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

(2017) Frederick E. Dewey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor)

(2017) Aurélie Thedrez et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Safety and efficacy of evinacumab, a monoclonal antibody to ANGPTL3, in patients with homozygous familial hypercholesterolemia receiving concomitant lipid-lowering therapies

(2016) Daniel Gaudet et al.   Journal of Clinical Lipidology

Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion

(2015) Yan Wang et al.   JOURNAL OF LIPID RESEARCH

ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys

(2015) Viktoria Gusarova et al.   JOURNAL OF LIPID RESEARCH

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Lipid Treatment Assessment Project 2

(2009) David D. Waters et al.   CIRCULATION